MS patients have an imbalance of Effector and Regulatory cells which causes nerve damage. The solution is a Novel small molecule STAT3 inhibitor, LLL12B, that improves Effector/Regulator cell balance. LLL12b significantly suppresses the disease progression in three murine MS model. There is a great opportunity for this solution as MS is prevalent in 300 people per every 100,000 in the US and is onset in the age range of 20-40.
